Aurobindo Pharma Ltd

NSE: AUROPHARMA LIVE

Healthcare & Pharma • • ISIN: N/A

₹1,734.00

▲ +54.20 (+2.60%)

Data updated: Just now (NSE India Live Feed)

52W Low: ₹1,066.80

Today High / Low: ₹1,734.00 / ₹1,676.10

52W High: ₹1,734.00

Volume: 1,209,478

⚖️ Compare vs Peers

🎯 TickerPulse Confluence Engine Institutional 360°

360° Quantitative Confluence Radar HIGH CONFLUENCE BULLISH SETUP

Exceptional confluence: Institutional accumulation aligned with trend moving averages and asymmetric >2.0 R:R payoff.

Confluence Score

Top Decile Edge

Valuation & Multiples 68/100

P/E, P/B, FCF yield vs historical levels

Trend & Moving Averages 96/100

20/50 EMA structure, RSI momentum, 52W range

Institutional Sponsorship 85/100

FII & DII holdings, delivery turnover backing

Balance Sheet Solvency 87/100

Debt-to-equity ratio, Altman Z score, operating margin

Asymmetric Reward-to-Risk 60/100

Calculated 1.68:1 potential target vs swing low stop

📐 Institutional Trade Setup 1% Risk Aligned

Entry Reference

₹1,734.00

Structural Stop Loss

₹1,630.83

Max Risk: -5.95%

Technical Target 1

₹1,907.40

Payoff Profile

1.68 : 1.0

Reward-to-Risk

🎯 Size This Trade (1% Risk Lab) → 🎮 Paper Trade Virtual Setup →

Transparent Business & Valuation Scoring

Methodology v1.0 • Every metric is deterministic and verifiable.

How we calculate scores →

Overall Quality Score

65 / 100

Moderate

Financial Health

82 / 100

Strong

Profitability & Margins

65 / 100

Moderate

Growth Trajectory

40 / 100

Subdued

Valuation Attractiveness

63 / 100

Moderate

Interactive Price Performance & Trend

Live exchange closing feeds from NSE/BSE

50-Day DMA: ₹1,673.31

200-Day DMA: ₹1,551.93

14-Day RSI: 61.1 (Neutral)

Trend: Strong Bullish

Key Fundamentals & Ratios (Data as of 2026-08-30)

Market Cap ₹8,600,000.00L Cr Large_cap Category

P/E Ratio (TTM) 24.5x Sector Mean: ~28.5x

Price to Book (P/B) — Book Val: ₹0.0

Return on Equity (ROE) 16.5% Net Profit / Net Worth

ROCE — Capital Efficiency

Debt / Equity 0.12 Manageable Leverage

EPS (TTM) ₹0.00 Earnings Per Share

Dividend Yield 0.45% Annual Cash Payout

Operating Margin — Core Operational Spread

Annual Free Cash Flow ₹0.00 Cr Operating CF minus Capex

Algorithmic Analysis (Pros & Cons)

⚡ Computed from Balance Sheet & Valuation Metrics

✓

Company Strengths (Pros)

• Company has maintained a healthy low debt-to-equity ratio of 0.12.
• Delivers solid shareholder returns with an ROE of 16.5%.

⚠

Key Limitations & Risks (Cons)

• Valuation is sensitive to broader macroeconomic and sectoral interest rate cycles.

Fundamental Health

Piotroski F-Score

6 / 9

Balance Sheet Score: Stable Financials

Positive Return on Equity (ROE) ✓ PASS

High Capital Efficiency (ROCE > 12%) ✗ FAIL

Strong Operating Spread (Margin > 15%) ✗ FAIL

Positive Free Cash Flow Generation ✓ PASS

9-Point Stanford University fundamental screening model.

Solvency & Credit Risk

Altman Z-Score

5.62

Solvency Classification: Safe Zone (Low Distress)

Firm exhibits exceptionally robust balance sheet solvency with near-zero short-term distress risk.

Safe Zone (>2.99) • Grey Zone (1.81–2.99) • Distress (<1.81)

Valuation Model

Intrinsic Fair Value

DCF + Graham

Estimated Fair Value

₹994.22

Premium / Overvalued (-42.7%)

Graham Value

₹888.23

DCF Model

₹1,080.94

DuPont ROE: 14.4% NPM × 0.85 Turn × 1.12x Lev

Quarterly Financial Performance (Consolidated ₹ Cr)

Past 4 Reported Quarters

Metric (₹ Cr)	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales / Revenue	₹8,997.75 Cr	₹9,384.75 Cr	₹9,868.50 Cr	₹10,255.50 Cr
Operating Profit	₹1,610.60 Cr	₹1,717.41 Cr	₹1,845.41 Cr	₹1,958.80 Cr
OPM % (Operating Margin)	17.9%	18.3%	18.7%	19.1%
Profit before Tax (PBT)	₹1,288.48 Cr	₹1,373.93 Cr	₹1,476.33 Cr	₹1,567.04 Cr
Net Profit (PAT)	₹966.36 Cr	₹1,030.45 Cr	₹1,107.25 Cr	₹1,175.28 Cr
Quarterly EPS (₹)	₹16.46	₹17.16	₹18.05	₹18.76

Shareholding Pattern & Institutional Ownership

Latest Disclosed Quarter

Promoters

52.40%

Foreign Institutions (FIIs)

19.80%

Domestic Institutions (DIIs)

15.60%

Retail & Public

12.20%

Technical Levels & Intraday Pivot Matrix

Institutional support, resistance, moving averages & momentum indicators

⚡ Signal: Strong Bullish RSI (14): 61.1

📈 Key Moving Averages

20 EMA (Short Term)

₹1,713.19

50 SMA (Medium Term)

₹1,673.31

100 SMA (Structural)

₹1,626.49

200 SMA (Long Trend)

₹1,551.93

🎯 52-Week Range Alignment

Distance from 52W High (₹1,734.00) 0%

Distance from 52W Low (₹1,066.80) +62.5%

Pivot Model	Support 3	Support 2	Support 1	Central Pivot (P)	Resistance 1	Resistance 2	Resistance 3
Classic Floor	₹1,637.50	₹1,656.80	₹1,695.40	₹1,714.70	₹1,753.30	₹1,772.60	₹1,811.20
Camarilla Intraday	—	L4: ₹1,702.16	L3: ₹1,718.08	₹1,734.00	H3: ₹1,749.92	H4: ₹1,765.85	—
Fibonacci	—	61.8%: ₹1,698.22	38.2%: ₹1,711.88	₹1,714.70	38.2%: ₹1,756.12	61.8%: ₹1,769.78	—

Sector Peers Comparison (Healthcare & Pharma)

Peer Company	Price	Today Change	Market Cap	P/E Ratio	ROE (%)	Compare
NEULANDLAB — NEULAND LAB Ltd.	₹22,840.00	▲ +0.00 (+0.77%)	₹115,050,000.00L Cr	28.5x	16.4%	Compare →
SUNPHARMA — Sun Pharmaceutical Industries Ltd	₹1,837.30	▼ 0.00 (-1.61%)	₹45,100,000.00L Cr	38.4x	17.8%	Compare →
ASTRAZEN — ASTRAZENECA PHARMA IND LT	₹6,751.50	▲ +0.00 (+1.24%)	₹34,757,500.00L Cr	28.5x	16.4%	Compare →
AJANTPHARM — AJANTA PHARMA Ltd	₹3,563.60	▲ +0.00 (+1.80%)	₹18,009,500.00L Cr	28.5x	16.4%	Compare →
GLAXO — GLAXOSMITHKLINE PHARMA LT	₹2,838.80	▲ +0.00 (+1.39%)	₹15,250,500.00L Cr	28.5x	16.4%	Compare →

Save to Your Watchlist

Aurobindo Pharma Ltd

360° Quantitative Confluence Radar HIGH CONFLUENCE BULLISH SETUP

Transparent Business & Valuation Scoring

Interactive Price Performance & Trend

Key Fundamentals & Ratios (Data as of 2026-08-30)

Algorithmic Analysis (Pros & Cons)

Company Strengths (Pros)

Key Limitations & Risks (Cons)

Piotroski F-Score

Altman Z-Score

Intrinsic Fair Value

Quarterly Financial Performance (Consolidated ₹ Cr)

Shareholding Pattern & Institutional Ownership

Technical Levels & Intraday Pivot Matrix

Sector Peers Comparison (Healthcare & Pharma)

About Aurobindo Pharma Ltd